INTRODUCTION
============

The early secretory pathway is formed by the endoplasmic reticulum (ER), the ER--Golgi intermediate compartment (ERGIC), and the Golgi, which have strikingly different structures ([@B39]; [@B4]; [@B3]). The ERGIC consists of a constant average number of discontinuous long-lived stationary tubulovesicular clusters that stain positive for the type I transmembrane lectin ERGIC-53 and for the cytosolic coat protein (COP) I subunit β-COP ([@B48]; [@B26]; [@B5]). The ERGIC is equivalent to the site at which ER-to-Golgi transport of some cargo proteins and receptors is reversibly blocked at 15°C ([@B28]; [@B49]; [@B32]; [@B26]; [@B6]; [@B5]; [@B52]). ERGIC stationary clusters operate as sorting stations of anterograde cargo directed to the Golgi and retrograde cargo directed to the ER ([@B5]). In addition, the stationary clusters communicate by fusion and fission and by fast-moving carriers, the function of which is unknown ([@B5]). Recently, the ERGIC was found to be more complex than anticipated, including a centrosomal connection that was proposed to mediate traffic to the recycling endosomes ([@B34]; [@B44]).

Various drugs affect the morphology of the ERGIC. For example, treating cells with the fungal metabolite brefeldin A (BFA) induces cycling proteins to accumulate in the ERGIC and increases the size of ERGIC clusters ([@B31]; [@B16]; [@B45]; [@B7]). BFA prevents the activation of ADP ribosylation factor (Arf) 1 by guanine exchange factors, thus blocking Arf1 in its guanosine diphosphate-inactive form ([@B41]; [@B58]). This prevents binding of COPI to membranes ([@B13]; [@B45]). A phenotype similar but not identical to BFA arises in HeLa cells after Arf1 and Arf4 knockdown. The double knockdown but not single knockdowns of Arf1 and Arf4 causes ß-COP to disperse throughout the cytosol ([@B56]). In that case, however, dispersal of β-COP was not reported to coincide with a change in the morphology of the ERGIC.

Temperature manipulations also can change the architecture of the ERGIC. In cells incubated at 15--16°C and rewarmed for short times to 37°C, tubules positive for the ERGIC marker ERGIC-53 are observed, indicating accentuated ERGIC-to-ER retrograde traffic ([@B31]; [@B49]; [@B26]; [@B5]; [@B52]). ERGIC tubules are also observed in cells knocked down for guanine nucleotide exchange factor ([@B54]), in cells overexpressing some cargo proteins or cargo receptors ([@B6]; [@B36]; [@B52]) as well as in cells expressing Rab1A ([@B43]).

The determinants of ER morphology, as a reticular network ([@B55]; [@B21]; [@B38]), and of the Golgi, as stacked cisternae ([@B19]), have been investigated for several years and with substantial but incomplete success, but those dictating the discontinuous nature of the ERGIC as a few hundred tubulovesicular clusters are unknown. Here, we show that Arf1, Arf4, and PLA2G6-A activity are necessary to maintain the discontinuous morphology of the ERGIC.

MATERIALS AND METHODS
=====================

Recombinant pSUPER Vectors
--------------------------

Standard molecular biology protocols were used. Oligonucleotides were from the Microsynth (Balgach, Switzerland) and enzymes were from New England Biolabs (Ipswich, MA). Construction of nuclear (nuc)ECFP was done as follows: 1) introduction of EcoRI and BamHI sites by polymerase chain reaction (PCR) amplification of S6-NLS ([@B24]), 2) ligation into pECFP-C1 (Clontech, Mountain View, CA), 3) addition of SpeI and SacII sites to the cytomegalovirus promoter-ECFP-NLS sequence, 4) ligation into TOPO-TA vector (Invitrogen, Carlsbad, CA), 5) ligation into pSUPER vectors in the antiparallel direction to the H1 promoter to avoid interferences with short hairpin RNA (shRNA) production, and 6) authentication by DNA sequencing.

Cell Culture, Transfection, and Knockdown
-----------------------------------------

HeLa cells were grown as described previously ([@B5]). FuGENE 6 (Roche Diagnostics, Basel, Switzerland) was used for transfections and knockdowns. Arf1+Arf4 double knockdowns were as described previously ([@B56]). In double knockdown experiments where two pSUPER vectors were cotransfected, only one of the vectors carried nucECFP. PLA2G6-A shRNAs were from Sigma-Aldrich (St. Louis, MO). PLA2G6-A knockdowns were for 48 h. When needed, PLA2G6-A shRNAs were cotransfected with pDsRedT1 (red fluorescent protein \[RFP\]) as a transfection marker. This was the case in rewarming experiments because the endogenous signal of PLA2G6-A was affected by the block and the rewarming. Myc-tagged mArf1 cDNA was from GeneCopoeia (Rockville, MD). Of note, mArf1 is resistant to human Arf1 shRNA, although it is identical to human Arf1 at the protein level. PLA2G6-A long splice variant (L-iPLA~2~) transfection was as described previously ([@B29]).

Immunofluorescence Microscopy
-----------------------------

Immunofluorescence microscopy was as described previously ([@B5]). The antibodies used were as follows: mouse monoclonal antibodies against CLIMP-63 ([@B47]), α-tubulin ([@B27]), myc ([@B22]), and GPP130 ([@B30]) and rabbit polyclonal antibodies against PLA2G6-A (H-120; Santa Cruz Biotechnology, Santa Cruz, CA), and Sec31 ([@B51]). H-120 antibody is predicted to detect an epitope at the N terminus of all PLA2G6-A splice variants. Phalloidin was from Invitrogen (Carlsbad, CA). Bright field images were taken with a DM5000B (63 × 1.32 numerical aperture \[NA\] oil lens; Leica, Wetzlar, Germany), and confocal images were taken with an SPE (63 × 1.3 NA oil lens; Leica). Unbiased quantification of GFP-ERGIC-53 tubules was as follows: 1) selection of cells with nucECFP signal or with RFP signal, 2) scoring of cells with tubules if they have at least one long peripheral GFP-ERGIC-53 tubule, and 3) blind tests to minimize subjective analyses; 100% represents the total of counted cells. Unless stated otherwise, data are presented as mean ± SD of at least three independent experiments. Statistical analysis was performed with either a Student\'s *t* test or with a Wilcoxon rank sum test using MATLAB software (The MathWorks, Natick, MA).

Live Cell Imaging, Transport Blocks, and Drug Treatment
-------------------------------------------------------

Imaging and processing were as described previously ([@B5]). Here, filters were applied to Supplemental Movies 2, 3, and 4. Block at 16°C and rewarming were as described previously ([@B5]). Nocodazole was from Fluka (Buchs, Switzerland); ONO-RS-082 was from BIOMOL International (Plymouth Meeting, PA); pyrrolidine-1 was from Calbiochem (San Diego, CA); and bromoenolactone (BEL) was from BIOMOL International. Egg [l]{.smallcaps}-α-lysophosphatidylcholine (LPC) was from Sigma-Aldrich (St. Louis, MO). All the drugs were diluted in HEPES-buffered Ham\'s F12 medium ([@B5]). LPC was introduced into cells as follows. A 40 mM LPC stock solution diluted in chloroform was dried by blowing it with nitrogen gas. It was then mixed with 1 mg/ml fatty acid-free bovine serum albumin (Sigma-Aldrich) diluted in HEPES-buffered Ham\'s F12 medium to a final concentration of 25 μM LPC. Cells were treated with this mixture combined with 50 μM BEL for 20 min at 37°C.

Immunoblotting and Immunoprecipitation
--------------------------------------

Arf1 and Arf4 immunoblotting was described previously ([@B56]). Quantification of knockdown efficiency was with the Odyssey program (Li-Cor Biosciences, Lincoln, NE). PLA2G6-A and myc immunoblotting was as follows. Cells were harvested at 4°C in lysis buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Na deoxycholate, and 1% NP40) supplemented with protease inhibitors. Lysates were then centrifuged 15 min at 14,000 × *g* at 4°C. Equal amounts of protein per lane were separated by SDS-polyacrylamide gel electrophoresis, immunoblotted, and visualized by enhanced chemiluminescence (Alpha Innotech, San Leandro, CA). PLA2G6-A was detected with P-19 antibody (Santa Cruz Biotechnology), the myc tag with anti-myc antibody ([@B22]), Arf4 with R-891 ([@B9]), and Arf1 with either R-1026 ([@B9]) or with a peptide antibody ([@B53]). Quantification was with Image Pro (Media Cybernetics, Bethesda, MD). For the immunoprecipitation, cells were transfected or not with mArf1, and supernatants of cell lysates were incubated with anti-PLA2G6-A (H-120) or anti-L-iPLA~2~ (T-14; Santa Cruz Biotechnology) coupled to protein G-Sepharose beads (Sigma-Aldrich). Beads were then washed with 1× phosphate-buffered saline and immunoblotted as described above.

RESULTS
=======

We studied the role of Arf1+Arf4 in controlling the ERGIC by using fluorescence microscopy and a knockdown approach. Because this method deals with single cells, proper detection of individual cells was required. To this end, we cloned into pSUPER vectors ECFP in frame with a nuclear localization signal (nucECFP). HeLa cells stably expressing GFP-ERGIC-53 transfected with Arf1+Arf4 shRNAs exhibited ∼80% reduction of both Arf1 and Arf4 ([Figure 1](#F1){ref-type="fig"}A) similarly to shRNAs not carrying the nuclear indicator ([@B56]), suggesting that nucECFP did not impair the knockdown efficiency. As predicted, nucECFP localized to the nucleus and to structures reminiscent of nucleoli ([Figure 1](#F1){ref-type="fig"}B). nucECFP expression did not affect the localization of GFP-ERGIC-53 in control pSUPER-transfected cells, suggesting that this indicator was appropriate to identify single transfected cells.

![Arf1+Arf4 double knockdown induces ERGIC tubules. (A) The protein level of both Arf1 and Arf4 (lower arrowheads) was reduced to ∼20% in HeLa cells stably expressing GFP-ERGIC-53 and cotransfected with Arf1+Arf4 shRNAs. Lysates were blotted with anti-Arf1, anti-Arf4, or as a loading control with anti-tubulin. (B) Arf1+Arf4 knockdown induces GFP-ERGIC-53-positive tubules (arrows), which connect ERGIC clusters (bottom panel, filled arrowheads). Such connections are restricted to some ERGIC clusters in knockdown cells and are absent in control cells (bottom panel, empty arrowheads). Bottom panels are magnifications of the highlighted regions. (C) Time series of live cells imaged every ∼3 s (from Supplemental Movie S1) where stationary ERGIC clusters connected (filled arrowheads) or not (empty arrowheads) by tubules are observed. The bottom panel is a magnification. (D--G) Confocal sections of knockdown cells as described in B stained for CLIMP-63 (D), Sec31 (E), GPP130 (F), or α-tubulin (G). GFP-ERGIC-53 do not colocalize with CLIMP-63, Sec31, or GPP130 (empty arrowheads in D-F). In some instances GFP-ERGIC-53-positive tubules colocalize with Sec31 spots or α-tubulin tubules (filled arrowheads in E and G). Insets and bottom panels are a magnification of the highlighted regions. pSUPER and Arf1 shRNA vectors carry nucECFP. Transfected cells were identified by nucECFP signal. Bars, 5 μm.](zmk0231096790001){#F1}

Arf1+Arf4 Silencing Induces Tubulation of the ERGIC
---------------------------------------------------

Fixed Arf1+Arf4 knockdown cells exhibited extensive GFP-ERGIC-53 tubules ([Figure 1](#F1){ref-type="fig"}B). A tubule was defined as a membrane structure ≥5 μm in length. Tubules seemed to connect peripheral ERGIC clusters. More than 80% of double knockdown cells showed GFP-ERGIC-53 tubules. On average, only 19% of control cells, 27% of Arf1 knockdown cells and 14% of Arf4 knockdown cells exhibited tubules (Supplemental Figure S1A), consistent with the previous findings that single knockdowns of Arf1 or Arf4 have no noticeable phenotype ([@B56]). Upon Arf1+Arf4 depletion, tubules were observed in two HeLa cell lines stably expressing GFP-ERGIC-53 as well as in parental HeLa cells stained for endogenous ERGIC-53 (Supplemental Figure S1B), indicating that the stable cells and parental HeLa cells behave indistinguishably. Thus, we think that tubulation of the ERGIC is a normal process that is highly accentuated in cells depleted of Arf1+Arf4.

Video microscopy of double knockdown cells showed that GFP-ERGIC-53 tubules were continuously elongating and shrinking ([Figure 1](#F1){ref-type="fig"}C and Supplemental Movie 1), suggesting that a tubule was a continuous entity rather than a string of vesicles. Occasionally, tubules elongated toward peripheral spots ([Figure 1](#F1){ref-type="fig"}C), confirming our observation with fixed cells that they connect ERGIC clusters. Tracking peripheral ERGIC spots revealed that Arf1+Arf4 knockdown did not alter the fission and fusion activity of GFP-ERGIC-53 stationary clusters (Supplemental Movie 2), and fast-moving carriers were still observed (Supplemental Movie 3). We conclude that Arf1+Arf4 act synergistically in cells to regulate the formation of ERGIC tubules.

To further characterize the tubules, we double labeled GFP-ERGIC-53 with markers of the secretory pathway. Arf1+Arf4 knockdown did not affect the morphology of ER or ER export sites (ERESs; [Figure 1](#F1){ref-type="fig"}, D and E). GFP-ERGIC-53 tubules did not colocalize with the ER marker CLIMP-63 ([Figure 1](#F1){ref-type="fig"}D), suggesting that these tubules were not ER-derived. ERESs, revealed by Sec31 staining, occasionally localized to GFP-ERGIC-53 tubules ([Figure 1](#F1){ref-type="fig"}E). This overlap was fortuitous because localization of Sec31 spots on a tubule was random, and tubules with no Sec31 staining were observed. A previous study of Arf1+Arf4 knockdown reported *cis*-Golgi GM130-positive tubules ([@B56]). However, GM130 can rapidly cycle between *cis*-Golgi and ERGIC ([@B35]), compromising the value of GM130 as a specific *cis*-Golgi marker. As a genuine *cis*-Golgi marker, we thus used the membrane protein GPP130 ([@B30]). In Arf1+Arf4 knockdown cells, GPP130 showed an unchanged Golgi pattern, and no colocalization with GFP-ERGIC-53 tubules was observed ([Figure 1](#F1){ref-type="fig"}F). Because the Golgi and the juxtanuclear accumulation of ERGIC clusters cannot be resolved by light microscopy, we focused our further analysis on peripheral ERGIC tubules at considerable distance from the Golgi.

In living cells, tubules were dynamic, suggesting that they moved along the cytoskeleton. To test this, we stained Arf1+Arf4 knockdown cells for tubulin and actin. The distribution of microtubules ([Figure 1](#F1){ref-type="fig"}G and Supplemental Figure S1C) and the actin cytoskeleton (Supplemental Figure S1D) was unchanged in these cells. GFP-ERGIC-53 tubules aligned with tubulin ([Figure 1](#F1){ref-type="fig"}G and Supplemental Figure S1C) but not with actin (Supplemental Figure S1D). Treatment with nocodazole, a microtubule-disruptive drug, inhibited GFP-ERGIC-53 tubules, whereas no inhibition was observed with the actin-disrupting chemical latrunculin B (Supplemental Figure S1, C and D). These results are most consistent with the conclusion that the ERGIC tubules that arise in cells depleted of Arf1+Arf4 move along microtubules.

To understand the role of ERGIC tubules upon Arf1+Arf4 knockdown, we studied a marker of the secretory pathway, ssDsRed, in which an N-terminal signal sequence was added to DsRed ([@B5]). ssDsRed accumulates in the ER and ERGIC when cells are cooled to 16°C and is sorted into anterograde transport carriers directed to the Golgi upon rewarming to 37°C ([@B5]). This is clearly the result of a sorting event and not fusion of ERGIC with other organelles as the ERGIC clusters persist upon rewarming. In control pSUPER-transfected cells ([Figure 2](#F2){ref-type="fig"}A and Supplemental Movie 4) or Arf1+Arf4-depleted cells ([Figure 2](#F2){ref-type="fig"}B and Supplemental Movie 5) briefly rewarmed to 37°C, ssDsRed localized to ER and ERGIC clusters. Occasionally in control cells, dual-labeled dynamic tubules connecting peripheral ERGIC clusters were observed ([Figure 2](#F2){ref-type="fig"}A). As the rewarming progressed, ERGIC clusters segregated ssDsRed without being consumed by the sorting event. In Arf1+Arf4-depleted cells, ssDsRed localized to tubules virtually all positive for GFP-ERGIC-53 ([Figure 2](#F2){ref-type="fig"}B). Conversely, not all GFP-ERGIC-53 tubules were positive for ssDsRed. We assume that the ssDsRed-negative tubules represent ERGIC-to-ER retrograde traffic ([@B5]). Double-labeled tubules emerging from a peripheral ERGIC cluster were often directed toward another ERGIC cluster with which they seemed to fuse ([Figure 2](#F2){ref-type="fig"}C). These tubules showed no substantial movement to the juxtanuclear Golgi region (Supplemental Movie 5). At later rewarming times, ERGIC clusters segregated ssDsRed carriers that moved to the Golgi ([Figure 2](#F2){ref-type="fig"}D). Like in control cells, the sorting event did not consume ERGIC stationary clusters ([Figure 2](#F2){ref-type="fig"}B and Supplemental Movie 5). Together, these observations indicate that cargo in the ERGIC can move between ERGIC clusters via tubules that are more numerous and persistent in Arf1+Arf4 knockdown cells.

![Arf1+Arf4 mediate traffic between ERGIC peripheral clusters. Time series of live cells extracted from Supplemental Movies S4 and S5. Control and knockdown cells were as described in [Figure 1](#F1){ref-type="fig"}B. They were in addition transfected with ssDsRed and incubated 3 h at 16°C followed by a shift to 37°C. Images were acquired every 3 s. (A) Arrows point to sorting ERGIC clusters. Arrowheads point to dual-labeled tubules. Insets are magnifications. (B) Arrows, dual-labeled tubules; dashed arrows, ERGIC clusters sorting ssDsRed without being consumed; arrowheads, ERGIC tubules devoid of ssDsRed. Insets, magnification of the highlighted region. (C) Arrows point to dual-labeled tubules connecting ERGIC clusters. Arrowheads point to ERGIC clusters. (D) Dashed arrows point to ssDsRed-positive anterograde carrier moving to the Golgi (G). Bars, 5 μm.](zmk0231096790002){#F2}

Role of Phospholipase A~2~ in ERGIC Tubulation
----------------------------------------------

Tubulation in the early secretory pathway is controlled by PLA~2~ activity ([@B12]), probably due to the generation of lysophospholipids, fusogenic inverted cone-shaped lipids produced by PLA~2~, on the outer leaflet of the lipid bilayer ([@B8]). To date two PLA~2~ groups were suggested to function in the early secretory pathway: group IV calcium Ca^2+^-dependent PLA~2~ (PLA2G4, also named cPLA~2~) and group VI Ca^2+^-independent PLA~2~ (PLA2G6, also named iPLA~2~) ([@B8]; [@B18]). To explore whether the tubules observed in response to Arf1+Arf4 silencing were due to these PLA~2~, we treated knockdown cells with ONO-RS-082, an inhibitor of these activities. ONO-RS-082 reduced the number of ERGIC tubules ([Figure 3](#F3){ref-type="fig"}B) as well as the percentage of cells with ERGIC tubules ([Figure 3](#F3){ref-type="fig"}F), suggesting that tubules were due to PLA~2~. PLA2G4 has six members named A--E. Only PLA2G4-A (also named cytosolic PLA~2~α) can associate with the Golgi ([@B14]) and was shown to control Golgi morphology and intracellular traffic ([@B10]; [@B42]). To determine whether the tubules were due to PLA2G4-A activity, we treated Arf1+Arf4 knockdown cells with pyrrolidine ([@B50]), which inhibits the activity of some PLA2G4 members without affecting the activity of PLA2G6 ([@B17]). Clearly, 20 μM pyrrolidine did not inhibit ERGIC tubules ([Figure 3](#F3){ref-type="fig"}C) and did not decrease the percentage of cells with GFP-ERGIC-53 tubules ([Figure 3](#F3){ref-type="fig"}F). Because HeLa cells have high levels of PLA2G4-A ([@B20]), we increased the concentration of pyrrolidine up to 160 μM. Even at this high concentration, no effect on ERGIC tubules was observed (Supplemental Figure S2), suggesting that PLA2G4-A activity is not controlling ERGIC tubulation in Arf1+Arf4 knockdown cells.

![ERGIC tubules induced by Arf1+Arf4 double knockdown are sensitive to some PLA~2~ antagonists. Cells were processed as described in [Figure 1](#F1){ref-type="fig"}D and were either untreated (A) or treated for 20 min with ONO-RS-082 (B), pyrrolidine (C), BEL (D), or BEL supplemented with LPC (E). Bar, 5 μm. Insets are magnifications of the highlighted regions. (F) 100% represents the total number of cells counted. Results are shown as mean ± SD of three to nine independent experiments. p values were calculated with a Wilcoxon rank test. The white bar represents pSUPER-transfected cells. Black bars represent Arf1+Arf4 knockdown cells.](zmk0231096790003){#F3}

BEL, a membrane permeable antagonist with a \>1000-fold selectivity for PLA2G6 over PLA2G4 ([@B1]), inhibits tubules in the early secretory pathway ([@B12]). Treatment of Arf1+Arf4 knockdown cells with 50 μM BEL inhibited ERGIC tubules ([Figure 3](#F3){ref-type="fig"}D) and reduced the percentage of cells with GFP-ERGIC-53 tubules down to ∼32% ([Figure 3](#F3){ref-type="fig"}F). This percentage was similar to that of pSUPER-transfected cells (∼28%), suggesting that tubules induced by Arf1+Arf4 depletion were dependent upon PLA2G6 activity.

LPC, a product of PLA2G6, bypasses the inhibition by BEL ([@B15]). To test whether this is also the case in Arf1+Arf4-depleted cells, we supplemented BEL-treated cells with LPC. BEL+LPC treatment restored GFP-ERGIC-53 tubules ([Figure 3](#F3){ref-type="fig"}E), and 63% of Arf1+Arf4 depleted cells treated with BEL+LPC showed GFP-ERGIC-53 tubules ([Figure 3](#F3){ref-type="fig"}F). This percentage was similar to untreated knockdown cells (69%), indicating that upon Arf1+Arf4 silencing, a product of PLA2G6 is necessary to induce ERGIC tubulation.

To pinpoint the PLA2G6 enzyme controlling ERGIC tubulation in vivo, we localized the endogenous A isoform of PLA2G6 (PLA2G6-A, also named iPLA~2~β). The B isoform (also named iPLA~2~γ) localizes to peroxisomes ([@B57]), ER, and mitochondria and responds to oxidative stress ([@B25]), rendering it less likely to control ERGIC tubulation upon Arf1+Arf4 depletion. In control cells, PLA2G6-A localized to peripheral puncta and to the Golgi region where it colocalized with juxtanuclear GFP-ERGIC-53 ([Figure 4](#F4){ref-type="fig"}A). In these cells, peripheral PLA2G6-A puncta were largely distinct from ERGIC clusters. In Arf1+Arf4 knockdown cells, PLA2G6-A accumulated in the juxtanuclear region and also localized to puncta ([Figure 4](#F4){ref-type="fig"}B). Strikingly, in these cells PLA2G6-A puncta colocalized with GFP-ERGIC-53 clusters. In addition, PLA2G6-A associated with extensions that partially overlapped with GFP-ERGIC-53 tubules, suggesting that PLA2G6-A acts at these sites.

![Arf1+Arf4 depletion affects PLA2G6-A localization, and PLAG6-A silencing inhibits ERGIC tubules. (A) Control cells were treated as described in [Figure 1](#F1){ref-type="fig"}B and stained with anti-PLA2G6-A. Arrowheads point to PLA2G6-A spots not colocalizing with ERGIC clusters. (B) Arf1+Arf4 knockdown cells were treated as described in [Figure 1](#F1){ref-type="fig"}D. Arrowheads point to PLA2G6-A spots and tubules colocalizing with ERGIC clusters and tubules. Right panels are magnifications of the highlighted regions. (C) Equal amounts of proteins from cell lysates were blotted with anti-PLA2G6-A (top) or with anti-Arf1 (bottom). (D) Quantification of the ratio L-iPLA~2~ to ankyrin-iPLA~2~. Values from Arf1+Arf4 knockdown cells were normalized to pSUPER-transfected cells, the values of which were set to 1. Results are shown as mean ± SD from four independent experiments. p values were calculated using a Wilcoxon rank test. (E and F) Knockdown cells as described in B were transfected with control (E) or L-iPLA~2~ (F) shRNAs. Bottom panels are magnifications of the highlighted regions. Bars, 5 μm.](zmk0231096790004){#F4}

PLA2G6A has multiple splice variants: long variants (L-iPLA~2~) and short variants (ankyrin-iPLA~2~) ([@B29]). If PLA2G6-A activity is high, ankyrin-iPLA~2~ protein levels are reduced. Thus, the L-iPLA~2~/ankyrin-iPLA~2~ ratio is proportional to PLA2G6-A activity ([@B33]; [@B40]). We visualized L-iPLA~2~ and ankyrin-iPLA~2~ expression by Western blotting. [Figure 4](#F4){ref-type="fig"}C shows that ankyrin-iPLA~2~ was reduced in Arf1+Arf4-depleted cells. The L-iPLA~2~/ankyrin-iPLA~2~ ratio was, on average, approximately threefold higher in knockdown cells ([Figure 4](#F4){ref-type="fig"}D), indicating that PLA2G6-A activity was increased upon Arf1+Arf4 silencing.

L-iPLA~2~ overexpression induces PLA2G6-A activity ([@B29]). We hypothesized that L-iPLA~2~ knockdown would decrease PLA2G6-A activity, and we tested whether L-iPLA~2~ controls ERGIC tubules. In cells depleted for L-iPLA~2~ and stained with an antibody recognizing all PLA2G6-A splice variants, PLA2G6-A fluorescence was reduced ([Figure 4](#F4){ref-type="fig"}F). Triple transfection with Arf1+Arf4 shRNAs and control shRNA did not affect ERGIC tubules ([Figure 4](#F4){ref-type="fig"}E). L-iPLA~2~ depletion inhibited ERGIC tubules in Arf1+Arf4 knockdown cells ([Figure 4](#F4){ref-type="fig"}F and Supplemental S3) and significantly reduced the percentage of cells with GFP-ERGIC-53 tubules (Supplemental Figure S3B), indicating that tubules are controlled by PLA2G6-A activity.

To explore the link between Arf1+Arf4 and PLA2G6-A, we attempted to rescue normal ERGIC morphology after Arf1+Arf4 depletion. Overexpression of mouse Arf1 (mArf1) in Arf1+Arf4 knockdown cells decreased ERGIC tubules threefold ([Figure 5](#F5){ref-type="fig"}, A--C), indicating that mArf1 rescues Arf1+Arf4 knockdown and thus mirrors an Arf4 single knockdown, which has no tubulation phenotype (Supplemental Figure S1A) ([@B56]). We also tested whether mArf1 expression restores PLA2G6-A activity, which would be expected if Arf1+Arf4 and PLA2G6-A were linked. [Figure 5](#F5){ref-type="fig"}D shows that ankyrin-iPLA~2~ level was increased in these cells. Quantification showed that expression of mArf1 reduces the L-iPLA~2~/ankyrin-iPLA~2~ ratio back to control levels ([Figure 5](#F5){ref-type="fig"}E), suggesting that mArf1 restores PLA2G6-A activity that in turn decreases ERGIC tubules. We hypothesized that Arf1 regulates PLA2G6-A activity by binding to it and tested whether Arf1 interacts with PLA2G6-A. Coimmunoprecipitation indeed showed that endogenous PLA2G6-A ([Figure 5](#F5){ref-type="fig"}F) and particularly endogenous L-iPLA~2~ can pull down a fraction of both mArf1 ([Figure 5](#F5){ref-type="fig"}G) and endogenous Arf1 ([Figure 5](#F5){ref-type="fig"}H).

![mArf1 rescues Arf1+Arf4 knockdown and interacts with PLA2G6-A. (A) Arf1+Arf4 knockdown cells as described in [Figure 1](#F1){ref-type="fig"}D were transfected with mArf1 and stained with anti-myc. (B) Cells as described in A mock transfected. Insets are magnifications of GFP-ERGIC-53 channel in the highlighted regions. Arrowheads point to tubules. Bar, 5 μm. (C) Knockdown cells were counted as described in [Figure 3](#F3){ref-type="fig"}F. Data are represented as mean ± SD from four to five independent experiments. The p value was calculated with a Wilcoxon rank test. (D) Same immunoblots as shown in [Figure 4](#F4){ref-type="fig"}C with the rescue condition in addition. (E) Quantification of the ratio L-iPLA~2~ to ankyrin-iPLA~2~ as described in [Figure 4](#F4){ref-type="fig"}D. Results are shown as mean ± SEM from four to eight independent experiments. p values were calculated using a Student\'s *t* test. (F) Cells transfected (+) or not (−) with mArf1 were lysed and immunoprecipitated with anti-PLA2G6-A (IP iPLA~2~) and blotted with anti-PLA2G6-A (top) or anti-myc (bottom). The total lysate (1%) is shown as a loading control. (G) Cells were processed as described in F and immunoprecipitated with anti-L-iPLA~2~ antibody (IP L-iPLA~2~). They were then immunoblotted as described in F. (H) Cells as described in F were immunoprecipitated with anti-L-iPLA~2~ antibody or as a negative control with anti-myc antibody. They were then immunoblotted with anti-PLA2G6-A (top) or anti-Arf1 (bottom).](zmk0231096790005){#F5}

Tubule formation at the ERGIC is not restricted to cells depleted of Arf1+Arf4. We and others have shown previously that in cells blocked at 15--16°C for a few hours and rewarmed briefly to 37°C, ERGIC tubules are generated ([@B31]; [@B49]; [@B26]; [@B5]; [@B52]). These tubules move between ERGIC clusters and mediate recycling from the ERGIC to the ER ([@B5]). To test whether these tubules also depend on PLA2G6, we stained cells blocked at 16°C and rewarmed to 37°C for 5 min with anti-PLA2G6-A antibody. As shown in [Figure 6](#F6){ref-type="fig"}A, in cells blocked at 16°C PLA2G6-A localized more often to ERGIC clusters than in control cells. Importantly, PLA2G6-A spots were observed on ERGIC tubules in cells rewarmed to 37°C. When cells were treated with BEL during the rewarming, no GFP-ERGIC-53 tubules were detected, in line with what was reported previously ([@B12]) and suggesting that traffic out of the ERGIC is mediated by PLA2G6-A activity. To corroborate this suggestion, we performed a 16°C/rewarming experiment in cells knocked down for PLA2G6-A. [Figure 6](#F6){ref-type="fig"}B shows that, contrary to control cells that exhibit long tubules, PLA2G6-A knockdown inhibits ERGIC tubules in cells rewarmed from 16°C. Quantification confirmed these observations and revealed that upon PLA2G6-A depletion, the percentage of cells with ERGIC tubules was significantly decreased ([Figure 6](#F6){ref-type="fig"}C). If appearance of ERGIC tubules is indeed controlled by PLA2G6-A, as our data indicate, then overexpression of L-iPLA~2~should induce at least some tubulation of the ERGIC. [Figure 6](#F6){ref-type="fig"}D shows that cells overexpressing L-iPLA~2~ indeed exhibit GFP-ERGIC-53 positive tubules that are positive for PLA2G6-A spots.

![PLA2G6-A controls tubulation of the ERGIC under conditions where Arf1+Arf4 are not depleted. (A) HeLa cells stably expressing GFP-ERGIC-53 were incubated or not at 16°C for 3 h and rewarmed or not in the presence or absence of BEL. Cells were then stained with anti-PLA2G6-A. Arrows point to GFP-ERGIC-53 tubules. Filled arrowheads point to PLA2G6-A spots colocalizing with ERGIC clusters. Empty arrowheads indicate PLA2G6-A spots connected to ERGIC tubules. Bottom panels are magnifications of the highlighted regions. (B) Cells were cotransfected with pDsRedT1 (RFP) and either a control shRNA or a shRNA targeting PLA2G6-A. Cells were then rewarmed from 16°C as described above. PLA2G6-A knockdown cells were identified by RFP signal. The arrowhead points to ERGIC tubules. Insets are magnifications of GFP-ERGIC-53 channel in the highlighted regions. (C) PLA2G6-A knockdown cells treated as described in B were counted as described in [Figure 3](#F3){ref-type="fig"}F. Data are represented as mean ± SD from five to six experiments. The p value was calculated using a Student\'s *t* test. (D) Cells were either mock transfected or transfected with L-iPLA~2~. Arrows point to GFP-ERGIC-53 tubules. Arrowheads point to PLA2G6-A spots localizing to ERGIC clusters and connected to ERGIC tubules. Insets are magnifications of the highlighted regions. Bars, 5 μm.](zmk0231096790006){#F6}

DISCUSSION
==========

These and previous findings ([@B5]) show that ERGIC clusters are relatively stable entities that communicate by means of dynamic tubules ([Figure 7](#F7){ref-type="fig"}). These ERGIC tubules are transient, and their formation is under regulation by both PLA2G6-A and Arf family GTPases. An increase in PLA2G6-A activity at ERGIC membranes leads to local changes in lipid composition, probably including increases in LPC. This leads to the formation of tubules that connect ERGIC clusters and through which cargo can move ([Figure 7](#F7){ref-type="fig"}B). The ERGIC tubules were found to align with microtubules and depend upon microtubules for their formation. We propose that the role of these tubules is to direct cargo, quickly and efficiently, to ERGIC clusters where cargo sorting can still occur. This could serve either to help equilibrate the composition of ERGIC clusters and their cargos throughout the cell or perhaps to more efficiently move cargos to clusters that are more actively engaged in sorting of cargos. Such a model suggests that under normal conditions, Arf1+Arf4 together regulate PLA2G6-A activity, thereby promoting the more discontinuous nature of ERGIC clusters ([Figure 7](#F7){ref-type="fig"}A). Arf1 and Arf4 were reported to localize to the ERGIC ([@B11]), consistent with the notion that they function in this compartment, although until now it was widely assumed that their function there was primarily to recruit COPI. Indeed, because Arf1+Arf4 silencing was shown to alter COPI recruitment to the early secretory pathway ([@B56]), it will probably prove interesting in future studies to determine whether COPI plays any role in the regulation of ERGIC tubulation. Such a role may be difficult to dissect or reconcile with its role in ERGIC to *cis*-Golgi traffic. However, because Arfs have been found to regulate both adaptor recruitment and changes in lipid-metabolizing enzymes at other sites, one could speculate that tubulation is a viable cellular alternative to carrier biogenesis that is controlled by Arf activities. Our data do not give a clear explanation of which forms of Arf1 and Arf4 control PLA2G6-A activity and how they would do so. Because active PLA2G6-A is thought to be a homotetramer ([@B2]), one could speculate that Arf1+Arf4 inhibit PLA2G6-A tetramerization by sequestering L-iPLA~2~ monomers. We think that this function is independent of the GTPase activity of Arf1 and/or Arf4 as was shown for the interaction of Arf1 with phospholipase D ([@B23]).

![Model of how Arf1, Arf4, and PLA2G6-A control ERGIC morphology. (A) Under steady-state conditions, ERGIC clusters (yellow) sort anterograde cargo (red) into anterograde carriers (AC) directed to the Golgi (red arrows) from retrograde cargo (green) into retrograde carriers (RC) directed to the ER (green arrows). Arf1 binds to PLA2G6-A, thus suppressing generation of ERGIC tubules. (B) Upon Arf1+Arf4 knockdown (or during rewarming from a 16°C block), PLA2G6-A becomes activated and changes the lipid composition of ERGIC membranes leading to tubules connecting ERGIC clusters. Cargo is transported via these tubules to ERGIC clusters that are still sorting-competent. ERGIC tubules move along microtubules (MT).](zmk0231096790007){#F7}

Effects of phospholipases on the secretory pathway were long believed to be indirect because the products of phospholipases stimulate various signal transduction pathways. However, recent findings point to direct effects of PLA~2~ and PLA~1~ ([@B37]; [@B42]; [@B46]), suggesting that different phospholipases control specific transport steps in the early secretory pathway. Here, we provide novel evidence for the involvement of PLA2G6-A in controlling the architecture of the ERGIC. Our findings indicate that in the ERGIC, a tight regulation of tubules is achieved through the interplay between Arf GTPases and PLA2G6-A. Such regulation might be an efficient way to flexibly cope with changes in the demands of membrane traffic.
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Arf

:   ADP ribosylation factor

BEL

:   bromoenolactone

BFA

:   brefeldin A

ERGIC

:   endoplasmic reticulum-Golgi intermediate compartment

L-iPLA~2~

:   PLA2G6-A long splice variant

LPC

:   lysophosphatidylcholine

mArf1

:   mouse Arf1

nucECFP

:   nuclear localized ECFP

PLA~2~

:   phospholipase A~2~

PLA2G4

:   group IV calcium Ca^2+^-dependent PLA~2~

PLA2G6

:   group VI calcium independent phospholipase A~2~.
